MCL1 and B-cell chronic lymphocytic leukemia: For example, ABT-737 markedly increased apoptosis in multiple myeloma,26 acute myeloid leukemia,8 chronic lymphocytic leukemia,27 and small cell lung cancer.28 However, resistance to ABT-737 in several types of cancer cell has been attributed to the high level of Mcl-1 expression.